B. Baier

Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.

M. Rezai, P. Fasching, L. Häberle, 2018, European journal of cancer.

Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients

M. Rezai, P. Fasching, L. Häberle, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study.

M. Rezai, M. Beckmann, P. Fasching, 2014, Geburtshilfe und Frauenheilkunde.

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

M. Rezai, M. Beckmann, P. Fasching, 2019, BMC Cancer.

Interest in Integrative Medicine Among Postmenopausal Hormone Receptor–Positive Breast Cancer Patients in the EvAluate-TM Study

M. Rezai, M. Beckmann, P. Fasching, 2016, Integrative cancer therapies.

First results from the Patient's Anastrozole Compliance to Therapy (PACT) program evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer (EBC).

M. Blettner, R. Kreienberg, M. Landthaler, 2010 .

Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study

M. Rezai, M. Beckmann, P. Fasching, 2019, BMC Cancer.

Survival of de novo stage IV breast cancer patients over three decades

M. Kiechle, N. Harbeck, I. Bauerfeind, 2016, Journal of Cancer Research and Clinical Oncology.

Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.

M. Rezai, M. Beckmann, P. Fasching, 2016, Breast care.

Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry

M. Kiechle, N. Harbeck, I. Bauerfeind, 2017, Journal of Cancer Research and Clinical Oncology.